T1	intervention 56 64	afatinib
T2	control 72 83	trastuzumab
T3	control 91 100	lapatinib
T4	outcome-Measure 975 998	objective response rate
T5	eligibility 666 754	Treatment-naive, HER2-positive BC patients with stage IIIA, B, C or inflammatory disease
T6	total-participants 1138 1140	29
T7	intervention-participants 1183 1185	10
T8	control-participants 1203 1204	8
T9	control-participants 1227 1229	11
T10	outcome 1232 1250	Objective response
T11	iv-bin-abs 1263 1264	8
T12	cv-bin-abs 1276 1277	6
T13	cv-bin-abs 1294 1295	4
T14	outcome 1346 1376	stable disease (best response)
T15	iv-bin-abs 1378 1379	1
T16	iv-bin-abs 1395 1396	1
T17	outcome 1429 1448	progressive disease
T18	outcome 1495 1522	drug-related adverse events
T19	iv-bin-abs 1454 1456	10
T20	cv-bin-abs 1588 1589	6
T21	control-participants 1593 1594	8
T22	cv-bin-abs 1630 1631	5
T23	control-participants 1635 1637	11
T24	outcome 1533 1579	diarrhea, dermatitis acneiform, and paronychia
T25	outcome 1607 1624	diarrhea and rash
T26	outcome 1668 1691	vomiting and arthralgia
